| Literature DB >> 35433806 |
Zhongtian Xiang1, Bo Wu1, Xiang Zhang1, Nan Feng1, Yiping Wei1, Jianjun Xu1, Wenxiong Zhang1.
Abstract
Background: Whether the utilization of preoperative three-dimensional (3D) lung simulation can improve the outcomes of segmentectomy for lung cancer (LC) is still controversial. Our meta-analysis was performed to compare preoperative 3D lung simulation with non-3D procedures in terms of perioperative outcomes.Entities:
Keywords: lung cancer; meta-analysis; segmentectomy; systematic review; three-dimensional lung simulation
Year: 2022 PMID: 35433806 PMCID: PMC9008247 DOI: 10.3389/fsurg.2022.856293
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Flow diagram of the research selection process.
Summary of the baseline characteristics of the included studies.
|
|
|
|
|
|
|
|
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||||||||||||
|
|
|
|
|
| |||||||||||||||
| 2021 | Wu et al. ( | China | 2020.1–2020.9 | 3D | 55 | 20/35 | 52.9 | 12 | – | 14 | 16 | 13 | – | 10 | – | 4 | 41 | – | – |
| Non-3D | 55 | 23/32 | 53.1 | 13 | – | 13 | 16 | 13 | – | 3 | – | 6 | 46 | – | |||||
| 2021 | Hu et al. ( | China | 2019.1–2020.8 | 3D | 30 | 14/16 | 61.3 | 10 | – | 3 | 14 | 3 | 1 | 3 | 23 | 4 | – | 5 | – |
| Non-3D | 35 | 16/19 | 62.7 | 11 | – | 4 | 20 | 5 | 2 | 5 | 22 | 5 | – | 6 | |||||
| 2020 | Chen et al. ( | China | 2016.3–2018.9 | 3D | 51 | 21/30 | 60.7 | 16 | – | 17 | 11 | 7 | – | – | – | – | – | – | – |
| Non-3D | 38 | 14/24 | 61.6 | 11 | – | 14 | 8 | 5 | – | – | – | – | – | – | |||||
| 2020 | Qiu et al. ( | China | 2017.4–2019.5 | 3D-model | 31 | 6/25 | 54.5 | 16 | 15 | 2 | 12 | – | 19 | 16 | – | 3.0 | |||
| 3D-RS | 131 | 42/89 | 54.4 | 54 | 77 | 4 | 35 | – | 87 | 48 | – | ||||||||
| Non-3D | 136 | 41/42 | 54.4 | 57 | 79 | 5 | 23 | – | 89 | 44 | – | ||||||||
| 2019 | Liu et al. ( | China | 2017.10–2018.8 | 3D-CT | 39 | 13/26 | 60.6 | 12 | – | 11 | 10 | 6 | 34 | 5 | – | ||||
| 3D-printing | 32 | 13/19 | 61.4 | 14 | – | 4 | 11 | 3 | 27 | 5 | |||||||||
| Non-3D | 53 | 19/34 | 62.1 | 18 | – | 11 | 13 | 11 | 45 | 8 | |||||||||
| 2019 | Xu et al. ( | China | 2017.7–2018.11 | 3D | 96 | 37/59 | 50.4 | 38 | – | 13 | 26 | 19 | – | – | – | 22 | 69 | – | – |
| Non-3D | 37 | 16/21 | 53.3 | 18 | – | 1 | 12 | 6 | – | – | – | 9 | 26 | – | |||||
| 2018 | Xue et al. ( | China | 2016.5–2017.2 | 3D | 36 | 9/27 | 53.0 | 12 | – | 6 | 13 | 5 | – | 5 | – | 8 | 23 | – | 17.5 |
| Non-3D | 32 | 12/20 | 51.6 | 10 | – | 5 | 12 | 5 | – | 5 | – | 9 | 18 | – | |||||
| 2018 | She et al. ( | China | 2014.1–2017.5 | 3D | 51 | 21/30 | 59.3 | 13 | – | 15 | 13 | 10 | 5 | 23 | 17 | – | – | 6 | 12.0 |
| Non-3D | 51 | 24/27 | 58.5 | 12 | – | 14 | 13 | 13 | 3 | 20 | 19 | – | – | 9 | |||||
3D, Three-dimensional; 3D-RS, 3D-reconstruction; M/F, male/female.
The number of patients in Histology (n) were inconsistent with the number of patients in Groups because some patients may have multiple lesions.
Methodological quality assessments of the included studies.
|
|
|
|
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||||||
| 2021 | Wu et al. ( | * | * | * | * | ** | * | 7 | |||||
| 2021 | Hu et al. ( | * | * | * | ** | * | 6 | ||||||
| 2020 | Chen et al. ( | ** | ** | * | 5 | ||||||||
| 2020 | Qiu et al. ( | * | * | * | ** | * | * | * | 8 | ||||
| 2019 | Liu et al. ( | * | * | * | ** | * | 6 | ||||||
| 2019 | Xu et al. ( | * | * | * | * | ** | * | 7 | |||||
| 2018 | Xue et al. ( | * | * | * | * | ** | * | * | * | 9 | |||
| 2018 | She et al. ( | * | * | * | * | ** | * | * | * | 9 | |||
Representativeness of the exposed cohort;
Selection of the non-exposed cohort;
Demonstration that outcome of interest was not present at start of study;
Comparability of cohorts on the basis of the design or analysis;
Was follow-up long enough for outcomes to occur.
Figure 2Forest diagrams of intraoperative indicators: blood loss (A), operative time (B), conversion (C), resected LNs (D).
Figure 3Forest plots of hospitalization indicators: postoperative hospital stay (A), complications (B), postoperative drainage time (C), postoperative drainage volume (D), and postoperative Forced Expiratory Volume in the first second (E).
Postoperative complications.
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||
| Pulmonary air leakage | 8 | 15/552 | 2.72% | 24/437 | 5.49% | 3.94% | 0.53 [0.28–1.01] | 0 | 0.05 |
| Pneumonia | 6 | 7/405 | 1.73% | 8/362 | 2.21% | 1.96% | 0.83 [0.33–2.08] | 0 | 0.69 |
| Atelectasis | 5 | 6/371 | 1.62% | 7/310 | 2.26% | 1.91% | 0.72 [0.26–2.01] | 0 | 0.53 |
| Hemoptysis | 4 | 3/207 | 1.45% | 16/194 | 8.25% | 4.74% | 0.19 [0.06–0.58] | 0 | 0.004 |
| Arrhythmia | 3 | 7/132 | 5.30% | 11/124 | 8.87% | 7.03% | 0.67 [0.28–1.60] | 0 | 0.37 |
| Atrial fibrillation | 2 | 2/91 | 2.20% | 0/87 | 0.00% | 11.23% | 2.83 [0.30–26.68] | 0 | 0.36 |
| Cerebral infarction | 2 | 2/147 | 1.36% | 1/75 | 1.33% | 1.35% | 0.91 [0.12–7.17] | 0 | 0.93 |
| Pulmonary infection | 2 | 3/147 | 2.04% | 2/75 | 2.67% | 2.25% | 0.75 [0.13–4.10] | 0 | 0.74 |
| Liquid pneumothorax | 1 | 1/96 | 1.04% | 0/37 | 0.00% | 0.75% | 1.18 [0.05–28.22] | – | 0.92 |
| Postoperative hemothorax | 1 | 1/96 | 1.04% | 0/37 | 0.00% | 0.75% | 1.18 [0.05–28.22] | – | 0.92 |
| Pleural effusion | 1 | 1/96 | 1.04% | 0/37 | 0.00% | 0.75% | 1.18 [0.05–28.22] | – | 0.92 |
CI, Confidence interval; COPD, Chronic obstructive pulmonary disease.